- Home
- ARVN vs RERE Comparison
ARVN vs RERE Comparison
Compare ARVN & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- RERE
- Stock Information
- Founded
- ARVN 2015
- RERE 2011
- Country
- ARVN United States
- RERE China
- Employees
- ARVN N/A
- RERE N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- ARVN Health Care
- RERE Consumer Discretionary
- Exchange
- ARVN Nasdaq
- RERE Nasdaq
- Market Cap
- ARVN 456.2M
- RERE 444.1M
- IPO Year
- ARVN 2018
- RERE 2021
- Fundamental
- Price
- ARVN $7.81
- RERE $3.64
- Analyst Decision
- ARVN Buy
- RERE
- Analyst Count
- ARVN 21
- RERE 0
- Target Price
- ARVN $20.53
- RERE N/A
- AVG Volume (30 Days)
- ARVN 1.8M
- RERE 2.7M
- Earning Date
- ARVN 07-29-2025
- RERE 08-19-2025
- Dividend Yield
- ARVN N/A
- RERE N/A
- EPS Growth
- ARVN N/A
- RERE N/A
- EPS
- ARVN N/A
- RERE 0.07
- Revenue
- ARVN $426,900,000.00
- RERE $2,388,301,386.00
- Revenue This Year
- ARVN $7.57
- RERE $27.37
- Revenue Next Year
- ARVN N/A
- RERE $24.06
- P/E Ratio
- ARVN N/A
- RERE $49.00
- Revenue Growth
- ARVN 498.74
- RERE 26.09
- 52 Week Low
- ARVN $5.90
- RERE $2.00
- 52 Week High
- ARVN $34.11
- RERE $4.35
- Technical
- Relative Strength Index (RSI)
- ARVN 54.65
- RERE 61.27
- Support Level
- ARVN $7.58
- RERE $3.49
- Resistance Level
- ARVN $8.31
- RERE $4.35
- Average True Range (ATR)
- ARVN 0.39
- RERE 0.30
- MACD
- ARVN 0.03
- RERE 0.02
- Stochastic Oscillator
- ARVN 64.75
- RERE 52.35
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.